Related Experiment Videos
Mitomycin is active against refractory germ-cell tumors. A phase II study
P Hoskins1, C M Coppin, N Murray
1Division of Medical Oncology, University of British Columbia, Vancouver, Canada.
American Journal of Clinical Oncology
|February 1, 1990
Abstract:
Mitomycin was used as single-agent therapy in seven male patients with nonseminomatous germ-cell tumors resistant to platinum analogues. The toxicity was high, especially hematological and pulmonary, in this heavily pretreated group. Mitomycin was active in this situation and one complete and one partial response of 18 and 20 weeks' duration, respectively, were seen.